Amicus Therapeutics
Current- Director 2018 to present
Skip to record
Executive record
Alpha ID: alpha:person:bradley-l-campbellVersion: public-0:d751713988987e9331980363e24189ceAs of: 2026-10-06
Not yet claimed16 published Claims7 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
- Professional RoleDirector at Amicus Therapeuticswww.sec.gov
- Board membershipServes on the board of Amicus TherapeuticsAmicus Therapeutics director board source +1 sources
- Board roleBoard role: DirectorFOLD DEF 14A director slate
- Committee assignmentsNo committee assignment disclosed in the cited filingFOLD DEF 14A director slate
Biography
More than four decades of experience in engineering, global aviation operations, and advanced aircraft development. Retired FedEx Captain with 30-year career in complex, high-consequence operational environments. Background as petroleum engineer focused on reservoir engineering and enhanced oil recovery.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- 2026 to end not publishedExecutive title: President and Chief Executive Officer · Organization not publishedFOLD DEF 14A director slate
- 2026 to end not publishedExecutive title: Director and Chairman of Compensation Committee · Organization not publishedHLEO 10-K executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
FOLD 10-K executive officers
sec filing · Source published: Feb 20, 2026 · Retrieved: May 15, 2026
Supports 2 claims
- Executive company: Executive at Amicus Therapeutics, Inc. · Claim reviewed: May 15, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
HLEO 10-K executive officers
sec filing · Source published: Feb 17, 2026 · Retrieved: May 16, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Helio Corp /FL/ · Claim reviewed: May 16, 2026
- Executive title: Executive title: Director and Chairman of Compensation Committee · Claim reviewed: May 16, 2026
- Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026
FOLD DEF 14A director slate
sec filing · Source published: Apr 24, 2025 · Retrieved: May 7, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Board role: Board role: Director · Claim reviewed: May 7, 2026
- Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 7, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Amicus Therapeutics, Inc. · Claim reviewed: May 15, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 7, 2026
Amicus Therapeutics director board source
sec filing · Source published: Apr 24, 2025 · Retrieved: May 3, 2026
Supports 2 claims
- Board independence: Not independent (executive director) · Claim reviewed: May 3, 2026
- Board membership: Serves on the board of Amicus Therapeutics · Claim reviewed: May 3, 2026
Open source
sec proxy · Source published: Apr 24, 2025 · Retrieved: May 1, 2026
Supports 1 claim
- Professional Role: Director at Amicus Therapeutics · Claim reviewed: May 16, 2026
FOLD executive roster source
sec filing · Source published: Date unavailable · Retrieved: May 3, 2026
Supports 5 claims
- AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
- AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
- Executive company: Executive at Amicus Therapeutics, Inc. · Claim reviewed: May 15, 2026
- Executive function: Enterprise Leadership (CEO) · Claim reviewed: May 3, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of Amicus Therapeutics · Claim reviewed: May 3, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-06
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- published
- Background screening
- out of scope